The DOI matches its Crossref record; 349 of the 349 references it cites were found in a registry or an index.
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Open accessAbstract
Despite scientific discoveries in the field of gene and cell therapy, some diseases still have no effective treatment. Advances in genetic engineering methods have enabled the development of effective gene therapy methods for various diseases based on adeno-associated viruses (AAVs). Today, many AAV-based gene therapy medications are being investigated in preclinical and clinical trials, and new ones are appearing on the market. In this article, we present a review of AAV discovery, properties, different serotypes, and tropism, and a following detailed explanation of their uses in gene therapy for disease of different organs and systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 3×
“It remains unknown what cellular receptors and coreceptors AAV10 and AAV11 use for cell binding and entry [37,115]; therefore, procedures describing their purification protocols are generally based on iodixanol gradient centrifugation [179].”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Członkowska, A., Litwin, T., Dusek, P., Ferenci, P., Lutsenko, S., Medici, V., Rybakowski, J. K., Weiss, K. H., & Schilsky, M. L. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0018-3 · Cited by 913
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
Samulski, R. J., Zhu, X., Xiao, X., Brook, J. D., Housman, D. E., Epstein, N., & Hunter, L. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04964.x · Cited by 784
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
CONGENITAL FAMILIAL NONHEMOLYTIC JAUNDICE WITH KERNICTERUS
Crigler, J. F., & Najjar, V. A. (1952) · PEDIATRICS · doi:10.1542/peds.10.2.169 · Cited by 548
Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B., & Ladenson, P. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2291 · Cited by 542
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Hoggan, M. D., Blacklow, N. R., & Rowe, W. P. (1966) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.55.6.1467 · Cited by 536
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Flotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., & Carter, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10613 · Cited by 490
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Rutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443 · cited 2×
“Similar to AAV2, this serotype uses HSPG, FGFR1, and LR receptors [60,74], along with the human HGFR (hHGFR) receptor [60].”
BackgroundAkache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., & Chiorini, J. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6884-6893.2001 · Cited by 427
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J.-D., Peerlinck, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113708 · Cited by 417
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Auricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403
Immunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Opie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364
Binding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic Acid Is Required for Gene Transfer
Walters, R. W., Yi, S. M. P., Keshavjee, S., Brown, K. E., Welsh, M. J., Chiorini, J. A., & Zabner, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101559200 · Cited by 363
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Identification of PDGFR as a receptor for AAV-5 transduction
Pasquale, G. D., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A., & Chiorini, J. A. (2003) · Nature Medicine · doi:10.1038/nm929 · Cited by 355 · cited 1×
“AAV5 was also found to use sialic acid as its primary receptor [88,100,101], along with platelet-derived growth factor receptors (PDGFR) α and β as coreceptors [102,103].”
BackgroundGrimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
In vivo tissue-tropism of adeno-associated viral vectors
Srivastava, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.003 · Cited by 347
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
Erles, K., Seb�kov�, P., & Schlehofer, J. R. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n · Cited by 342
Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Spinal Muscular Atrophy: A Timely Review
Kolb, S. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.74 · Cited by 333
Cloning and Characterization of Adeno-Associated Virus Type 5
Chiorini, J. A., Kim, F., Yang, L., & Kotin, R. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1309-1319.1999 · Cited by 332
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Wu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328
Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Zsebo, K., Yaroshinsky, A., Rudy, J. J., Wagner, K., Greenberg, B., Jessup, M., & Hajjar, R. J. (2014) · Circulation Research · doi:10.1161/circresaha.113.302421 · Cited by 315
Zabner, J., Seiler, M., Walters, R., Kotin, R. M., Fulgeras, W., Davidson, B. L., & Chiorini, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3852-3858.2000 · Cited by 315
Halbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314
Pondering the Promyelocytic Leukemia Protein (PML) Puzzle: Possible Functions for PML Nuclear Bodies
Borden, K. L. B. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5259-5269.2002 · Cited by 313
rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice
Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., Finn, E., Adams, M. E., Froehner, S. C., Murry, C. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1439 · Cited by 307
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Biology of Adeno-associated Virus
Berns, K. I., & Giraud, C. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80207-2_1 · Cited by 305
Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model
Akil, O., Dyka, F., Calvet, C., Emptoz, A., Lahlou, G., Nouaille, S., Boutet de Monvel, J., Hardelin, J.-P., Hauswirth, W. W., Avan, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817537116 · Cited by 300
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Bish, L. T., Morine, K., Sleeper, M. M., Sanmiguel, J., Wu, D., Gao, G., Wilson, J. M., & Sweeney, H. L. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.123 · Cited by 292
Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9
Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., & Asokan, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210922 · Cited by 282
Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.022 · Cited by 277
Niemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128577 · Cited by 266
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
Intracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255
Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 255
Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251
Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.609-614.2005 · Cited by 246 · cited 4×
“The developed strategies suggested different approaches, mainly, capsid modification of AAV3 vectors [76,80,81] and modification of hHGFR expression levels, along with the tyrosine kinase activity associated with it [78].”
BackgroundInfluentialNovel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246
Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 246
Mori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004) · Virology · doi:10.1016/j.virol.2004.10.012 · Cited by 245
Humoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
Aitken, M. L., Moss, R. B., Waltz, D. A., Dovey, M. E., Tonelli, M. R., McNamara, S. C., Gibson, R. L., Ramsey, B. W., Carter, B. J., & Reynolds, T. C. (2001) · Human Gene Therapy · doi:10.1089/104303401753153956 · Cited by 239
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
Pleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002097 · Cited by 234
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., & Kotin, R. M. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6823-6833.1997 · Cited by 231
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus
Wagner, J. A., Reynolds, T., Moran, M. L., Moss, R. B., Wine, J. J., Flotte, T. R., & Gardner, P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77740-0 · Cited by 225
Wang, Z., Kuhr, C. S., Allen, J. M., Blankinship, M., Gregorevic, P., Chamberlain, J. S., Tapscott, S. J., & Storb, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300161 · Cited by 218
DNA amplification of adeno-associated virus as a response to cellular genotoxic stress.
Yalkinoglu, A. Ö., Heilbronn, R., Bürkle, A., Schlehofer, J. R., & Hausen, H. Z. (1988) · PubMed · Cited by 218
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Bartus, R. T., Baumann, T. L., Siffert, J., Herzog, C. D., Alterman, R., Boulis, N., Turner, D. A., Stacy, M., Lang, A. E., Lozano, A. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182904faa · Cited by 215
Wang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
Intravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212
A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
Yang, L., Jiang, J., Drouin, L. M., Agbandje-Mckenna, M., Chen, C., Qiao, C., Pu, D., Hu, X., Wang, D.-Z., Li, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813207106 · Cited by 210
Vandendriessche, T., Thorrez, L., Acosta‐Sanchez, A., Petrus, I., Wang, L., Ma, L., De Waele, L., Iwasaki, Y., Gillijns, V., Wilson, J. M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02220.x · Cited by 209
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy
Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, T., Allen, J., Surosky, R., Lochrie, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0495 · Cited by 208
Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., & Davidson, B. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.15.7651-7660.2002 · Cited by 204
Recombinant AAV-mediated gene delivery to the central nervous system
Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T., Brotchi, J., & Levivier, M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.506 · Cited by 204
Daly, T. M., Vogler, C., Levy, B., Haskins, M. E., & Sands, M. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2296 · Cited by 204
Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Jiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C. D., Powell, S., Keller, T., McMurray, M., Labelle, A., et al. (2006) · Blood · doi:10.1182/blood-2005-12-5115 · Cited by 200
Walsh, C. E., Liu, J. M., Xiao, X., Young, N. S., Nienhuis, A. W., & Samulski, R. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7257 · Cited by 198
Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., & Henning, P. P. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300331 · Cited by 196
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190
Characterization of the DNA of a defective human parvovirus isolated from a genital site
Bantel-Schaal, U., & Zur Hausen, H. (1984) · Virology · doi:10.1016/0042-6822(84)90271-x · Cited by 188
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
Limberis, M. P., Vandenberghe, L. H., Zhang, L., Pickles, R. J., & Wilson, J. M. (2009) · Molecular Therapy · doi:10.1038/mt.2008.261 · Cited by 184
Adeno-Associated Virus (AAV) Vectors in the CNS
McCown, T. (2005) · Current Gene Therapy · doi:10.2174/1566523054064995 · Cited by 184
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Suzuki, J., Hashimoto, K., Xiao, R., Vandenberghe, L. H., & Liberman, M. C. (2017) · Scientific Reports · doi:10.1038/srep45524 · Cited by 173
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., & Samulski, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4421-4432.2004 · Cited by 171
Lalwani, A. K., Walsh, B., Reilly, P. G., Muzyczka, N., & Mhatre, A. N. (1996) · PubMed · Cited by 169
Scalable Purification of Adeno-Associated Virus Type 2, 4, or 5 Using Ion-Exchange Chromatography
Kaludov, N., Handelman, B., & Chiorini, J. A. (2002) · Human Gene Therapy · doi:10.1089/104303402320139014 · Cited by 167
Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates
Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino-Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000112 · Cited by 166
Serologic Evidence for Human Infection With Adenovirus-Associated Viruses
(1968) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/40.2.319 · Cited by 166
Samaranch, L., Salegio, E. A., Sebastián, W. S., Kells, A. P., Bringas, J. R., Forsayeth, J., & Bankiewicz, K. S. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.005 · Cited by 165
Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., & Chiorini, J. A. (2008) · Journal of Virology · doi:10.1128/jvi.02012-07 · Cited by 165
Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A. (2017) · Scientific Reports · doi:10.1038/srep45329 · Cited by 164
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2014) · Molecular Therapy · doi:10.1038/mt.2013.281 · Cited by 164
Electron cryo‐microscopy and image reconstruction of adeno‐associated virus type 2 empty capsids
Kronenberg, S., Kleinschmidt, J. A., & Böttcher, B. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve234 · Cited by 161
Effective gene therapy in an authentic model of Tay-Sachs-related diseases
Cachón-González, M. B., Wang, S. Z., Lynch, A. G., Ziegler, R. J., Cheng, S. H., & Cox, T. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603765103 · Cited by 161
Adeno-associated virus serotypes for gene therapeutics
Lisowski, L., Tay, S. S., & Alexander, I. E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.006 · Cited by 159
Adeno-associated virus: integration at a specific chromosomal locus
Samulski, R. J. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80344-2 · Cited by 159
Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3
Muramatsu, S.-I., Mizukami, H., Young, N. S., & Brown, K. E. (1996) · Virology · doi:10.1006/viro.1996.0367 · Cited by 159
Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain
Wang, C., Wang, C.-M., Clark, K. R., & Sferra, T. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302011 · Cited by 158
Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo
Palomeque, J., Chemaly, E. R., Colosi, P., Wellman, J. A., Zhou, S. Z., del Monte, F., & Hajjar, R. J. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302895 · Cited by 158
Adeno-associated viral vectors as gene delivery vehicles.
Carter, P. J., & Samulski, R. J. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.6.1.17 · Cited by 157
Limberis, M. P., & Wilson, J. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601433103 · Cited by 157
Tratschin, J.-D., Miller, I. L., Smith, M. G., & Carter, B. J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.3251 · Cited by 153
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins
Auricchio, A., O’Connor, E., Weiner, D. J., Gao, G., Hildinger, M., Wang, L., Calcedo, R., & Wilson, J. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15780 · Cited by 152
Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward
Cooney, A. L., McCray, P. B., & Sinn, P. L. (2018) · Genes · doi:10.3390/genes9110538 · Cited by 152
Zincarelli, C., Soltys, S., Rengo, G., Koch, W. J., & Rabinowitz, J. E. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00190.x · Cited by 151
Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches
Shaimardanova, A. A., Chulpanova, D. S., Solovyeva, V. V., Mullagulova, A. I., Kitaeva, K. V., Allegrucci, C., & Rizvanov, A. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.576221 · Cited by 151
Self-citationSong, S., Embury, J. E., Laipis, P., Berns, K., Crawford, J., & Flotte, T. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301422 · Cited by 150
Parvovirus glycan interactions
Huang, L., Halder, S., & Agbandje‐McKenna, M. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.05.007 · Cited by 150
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
Structural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKENNA, R. V., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje‐McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 149
Handa, A., Muramatsu, S., Qiu, J., Mizukami, H., & Brown, K. E. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-8-2077 · Cited by 148
Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference
Borel, F., Kay, M. A., & Mueller, C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.285 · Cited by 147
Griffey, M. A., Wozniak, D. F., Wong, M., Bible, E., Johnson, K. N., Rothman, S. M., Wentz, A. E., Cooper, J. D., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.008 · Cited by 147
Bantel‐Schaal, U., Hub, B., & Kartenbeck, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2340-2349.2002 · Cited by 144
Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid
Bell, C. L., Gurda, B. L., Vliet, K. V., Agbandje‐McKenna, M., & Wilson, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.00448-12 · Cited by 143
Gene transfer into skeletal muscle using novel AAV serotypes
Louboutin, J., Wang, L., & Wilson, J. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.686 · Cited by 143
Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors
Alisky, J. M., Hughes, S. M., Sauter, S. L., Jolly, D. J., Dubensky, T. W., Staber, P. D., Chiorini, J. A., & Davidson, B. L. (2000) · Neuroreport · doi:10.1097/00001756-200008210-00013 · Cited by 142
Chien, Y.-H., Lee, N.-C., Tseng, S.-H., Tai, C.-H., Muramatsu, S.-I., Byrne, B. J., & Hwu, W.-L. (2017) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(17)30125-6 · Cited by 142
AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression
Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., Lorenc, V. E., Chen, D., Chadha, R., Zhang, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129085 · Cited by 141
Comparison of Adenoviral and Adeno-Associated Viral Vectors for Pancreatic Gene Delivery In Vivo
Wang, A. Y., Peng, P. D., Ehrhardt, A., Storm, T. A., & Kay, M. A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959551 · Cited by 141
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6
Weller, M. L., Amornphimoltham, P., Schmidt, M., Wilson, P. A., Gutkind, J. S., & Chiorini, J. A. (2010) · Nature Medicine · doi:10.1038/nm.2145 · Cited by 140
The Role of the Adeno-Associated Virus Capsid in Gene Transfer
Vliet, K. V., Blouin, V., Brument, N., Agbandje‐McKenna, M., & Snyder, R. O. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_2 · Cited by 138
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Skorupa, A. F., Fisher, K. J., Wilson, J. M., Parente, M. K., & Wolfe, J. H. N. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7176 · Cited by 137
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Davidoff, A. M., Ng, C. Y., Sleep, S., Gray, J. T., Azam, S. A., Zhao, Y., McIntosh, J., Karimipoor, M., & Nathwani, A. C. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.07.001 · Cited by 135
Building a Better Vector: The Manipulation of AAV Virions
Rabinowitz, J. E., & Samulski, R. J. (2000) · Virology · doi:10.1006/viro.2000.0707 · Cited by 134
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
De, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., & Crystal, R. G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.003 · Cited by 129
Liu, Y., Okada, T., Sheykholeslami, K., Shimazaki, K., Nomoto, T., Muramatsu, S., Kanazawa, T., Takeuchi, K., Ajalli, R., Mizukami, H., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.021 · Cited by 129
New Approaches to Tay-Sachs Disease Therapy
Solovyeva, V. V., Shaimardanova, A. A., Chulpanova, D. S., Kitaeva, K. V., Chakrabarti, L., & Rizvanov, A. A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01663 · Cited by 129
Self-citationBantel-Schaal, U., Delius, H., Schmidt, R., & zur Hausen, H. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.939-947.1999 · Cited by 128
Adeno-Associated Virus Type 2 Protein Interactions: Formation of Pre-Encapsidation Complexes
Dubielzig, R., King, J., Weger, S., Kern, A., & Kleinschmidt, J. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.8989-8998.1999 · Cited by 127
Griffey, M. A., Bible, E., Vogler, C. A., Levy, B. K., Gupta, P. K., Cooper, J. D., & Sands, M. S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.03.005 · Cited by 127
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Choudhury, S., Fitzpatrick, Z., Harris, A. F., Maitland, S. A., Ferreira, J. S., Zhang, Y., Ma, S., Sharma, R. B., Gray‐Edwards, H. L., Johnson, J. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.84 · Cited by 125
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Mietzsch, M., Broecker, F., Reinhardt, A., Seeberger, P., & Heilbronn, R. (2013) · Journal of Virology · doi:10.1128/jvi.03371-13 · Cited by 122
Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease
Prado, D. A., Acosta-Acero, M., & Maldonado, R. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000660 · Cited by 120
Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features
Mietzsch, M., Jose, A., Chipman, P. R., Bhattacharya, N., Daneshparvar, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Viruses · doi:10.3390/v13010101 · Cited by 117
Structure of Adeno-Associated Virus Type 4
Padron, E., Bowman, V. D., Kaludov, N. K., Govindasamy, L., Levy, H. C., Nick, P., McKENNA, R. V., Muzyczka, N., Chiorini, J. A., Baker, T. S., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5047-5058.2005 · Cited by 116
A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna
Taghian, T., Marosfoi, M. G., Puri, A. S., Cataltepe, O. I., King, R. M., Diffie, E. B., Maguire, A. S., Martin, D. R., Fernau, D., Batista, A. R., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.012 · Cited by 115
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114 · cited 3×
“The developed strategies suggested different approaches, mainly, capsid modification of AAV3 vectors [76,80,81] and modification of hHGFR expression levels, along with the tyrosine kinase activity associated with it [78].”
BackgroundMethodLogan, G. J., Dane, A. P., Hallwirth, C. V., Smyth, C. M., Wilkie, E. E., Amaya, A. K., Zhu, E., Khandekar, N., Ginn, S. L., Liao, S. H. Y., et al. (2017) · Nature Genetics · doi:10.1038/ng.3893 · Cited by 113
Chen, S., Kapturczak, M., Loiler, S., Zolotukhin, S., Glushakova, O. Y., Madsen, K., Samulski, R. J., Hauswirth, W. W., Campbell‐Thompson, M., Berns, K. I., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.235 · Cited by 112
Okada, T., Nonaka‐Sarukawa, M., Uchibori, R., Kinoshita, K., Hayashita‐Kinoh, H., Nitahara‐Kasahara, Y., Takeda, S., & Ozawa, K. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.006 · Cited by 110
Pañeda, A., Vanrell, L., Mauleon, I., Crettaz, J. S., Berraondo, P., Timmermans, E. J., Beattie, S. G., Twisk, J., van Deventer, S., Prieto, J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.031 · Cited by 109
Rafi, M. A., Rao, H. Z., Passini, M. A., Curtis, M. T., Vanier, M. T., Zaka, M., Luzi, P., Wolfe, J. H. N., & Wenger, D. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.020 · Cited by 109
Ge, L., Yang, F., Li, W., Wang, T., Lin, Y. H., Feng, J., Chen, N., Jiang, M., Wang, J., Hu, X., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590008 · Cited by 109
Nam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108
Mary, B., Maurya, S., Arumugam, S., Kumar, V. S., & Jayandharan, G. R. (2019) · FEBS Journal · doi:10.1111/febs.15013 · Cited by 108
Rubin, J. D., Nguyen, T. V., Allen, K. L., Ayasoufi, K., & Barry, M. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.127 · Cited by 108
Kyöstió, S. R., Owens, R. A., Weitzman, M. D., Antoni, B. A., Chejanovsky, N., & Carter, B. J. (1994) · Journal of Virology · doi:10.1128/jvi.68.5.2947-2957.1994 · Cited by 106
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins
Auricchio, A., O’Connor, E., Weiner, D. J., Gao, G., Hildinger, M., Wang, L., Calcedo, R., & Wilson, J. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215780 · Cited by 106
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A. R., Ng, R., Miller, E. B., Halder, S., McKENNA, R. V., Asokan, A., & Agbandje‐McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 105
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Kitaeva, K. V., Solovyeva, V. V., Blatt, N. L., & Rizvanov, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010643 · Cited by 7
Self-citation
Metadata
- Authors
- Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-03-01
- Volume
- 12
- Issue
- 5
- Pages
- 785
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4322770338
- Cited by
- 313
- References
- 349
- FWCI
- 45.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.